Short answer
Disc Medicine, Inc. (IRON) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$62M
- −134.3% YoY · −12.8% QoQ
- EPS (diluted)
- −$1.78
- −104.6% YoY · −11.9% QoQ
Source: XBRL data from the Disc Medicine, Inc. (IRON) Q3 2025 10-Q on SEC EDGAR. USD.
Disc Medicine, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability or margin figures presented in provided text
- No segment or product line performance details mentioned
- No management commentary on near-term outlook or updated guidance
Risk Factors
- New risk: Rapid NDA filing for bitopertin in EPP and XLP in Sept 2025 with FDA's National Priority Voucher accelerates review to 1-2 months, increasing near-term regulatory pressure
- Updated financial risk: Entered $200M senior secured Hercules Loan in Nov 2024 with maturity Dec 2029, including restrictive covenants and minimum qualified cash requirements
- Regulatory risk: Potential FDA or TGA demands for additional preclinical studies beyond Roche data could delay marketing approvals for bitopertin
- Operational risk: Uncertainty in completing Phase 3 and pivotal clinical trials; reliance on limited open-label Phase 2 studies raises risk to approval timelines
- Financial risk: Cash runway extends into 2029 including 2025 public offering proceeds, but accelerating commercialization expenses for bitopertin may elevate future capital needs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Disc Medicine, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.